CGEN Stock Forecast 2025-2026
Distance to CGEN Price Targets
CGEN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Compugen (CGEN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CGEN and similar high-potential opportunities.
Latest CGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, CGEN has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). Currently trading at $1.47, the median forecast implies a 172.1% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Asthika Goonewardene at Truist Securities, projecting a 172.1% upside. Conversely, the most conservative target is provided by Asthika Goonewardene at Truist Securities, suggesting a 172.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGEN Analyst Ratings
CGEN Price Target Range
Latest CGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $4.00 |
| Mar 8, 2024 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $5.00 |
| Dec 19, 2023 | Stifel | Stephen Willey | Buy | Maintains | $4.00 |
| Aug 23, 2023 | Truist Securities | Asthika Goonewardene | Buy | Reiterates | $4.00 |
| Aug 7, 2023 | EF Hutton | Buy | Reiterates | $0.00 | |
| Jun 6, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $13.00 |
| May 26, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $13.00 |
| May 24, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $13.00 |
| May 16, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $7.00 |
| Feb 28, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $8.00 |
| Feb 8, 2023 | Jefferies | Chris Howerton | Underperform | Downgrade | $0.50 |
| Jan 5, 2023 | EF Hutton | Tony Butler | Buy | Initiates | $13.00 |
| Nov 15, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $8.00 |
| Aug 23, 2022 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $4.00 |
| Aug 8, 2022 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $4.00 |
| Aug 8, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $12.00 |
| Aug 5, 2022 | Jefferies | Hold | Downgrade | $0.00 | |
| Feb 25, 2022 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $9.00 |
| Feb 25, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $14.00 |
| Apr 6, 2021 | SVB Leerink | Daina Graybosch | Outperform | Maintains | $16.00 |
Compugen Ltd. (CGEN) Competitors
The following stocks are similar to Compugen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Compugen Ltd. (CGEN) Financial Data
Compugen Ltd. has a market capitalization of $143.75M with a P/E ratio of 60.3x. The company generates $27.86M in trailing twelve-month revenue with a -51.1% profit margin.
Revenue growth is -95.6% quarter-over-quarter, while maintaining an operating margin of -508.7% and return on equity of -23.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Compugen Ltd. (CGEN) Business Model
About Compugen Ltd.
Develops novel therapeutics for cancer immunotherapy.
Compugen Ltd. utilizes a predictive computational discovery platform to identify new drug targets and biomarkers. This innovative approach allows the company to streamline the drug development process, generating revenue through collaborations with pharmaceutical companies to develop and market new cancer treatments.
Based in Israel with operations in the United States, Compugen is a leader in precision medicine and immuno-oncology, emphasizing the importance of tailoring treatments to individual patient needs. Its collaborations with major pharmaceutical companies enhance its influence and capability in the biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Anat Cohen-Dayag Ph.D.
Country
Israel
IPO Year
2000
Website
cgen.comCompugen Ltd. (CGEN) Latest News & Analysis
Compugen Ltd. (Nasdaq: CGEN) will participate in virtual investor conferences in April 2025, focusing on cancer immunotherapy and computational target discovery.
Compugen's participation in investor conferences signals potential updates on clinical advancements and strategic initiatives, which could influence investor sentiment and stock performance.
Compugen Ltd. (NASDAQ:CGEN) will hold its Q4 2024 earnings conference call on March 4, 2025, at 8:30 AM ET. Key executives will participate in the call.
The upcoming earnings call for Compugen Ltd. on March 4, 2025, may provide key insights into financial performance and strategic direction, influencing investor sentiment and stock price movements.
Compugen Ltd. (Nasdaq: CGEN) reported positive clinical data for its anti-PVRIG antibody COM701, set to enter a trial in Q2 2025. The company maintains a cash runway into 2027.
Positive clinical data and ongoing trials for potential first-in-class therapies indicate strong growth prospects for Compugen, enhancing investor confidence and potential stock value.
Compugen (CGEN) reported a quarterly loss of $0.07 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.11 per share in the same quarter last year.
Compugen's quarterly loss aligns with estimates but reflects a decline from previous earnings, indicating potential challenges in growth and profitability, which may affect investor confidence.
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
1 month agoCompugen Ltd. (NASDAQ: CGEN) will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 8:00 AM ET.
Compugen's participation in a major healthcare conference could signal potential insights into its immunotherapy developments, influencing investor sentiment and stock performance.
Compugen and Ultima combined their AI and sequencing technologies to enhance tumor biology and immune regulation understanding, showing consistent single-cell expression levels.
The collaboration between Compugen and Ultima enhances tumor biology understanding, potentially improving cancer therapies and diagnostics, which could positively impact their stock value and market position.
Frequently Asked Questions About CGEN Stock
What is Compugen Ltd.'s (CGEN) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Compugen Ltd. (CGEN) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is CGEN stock a good investment in 2025?
According to current analyst ratings, CGEN has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGEN stock?
Wall Street analysts predict CGEN stock could reach $4.00 in the next 12 months. This represents a 172.1% increase from the current price of $1.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compugen Ltd.'s business model?
Compugen Ltd. utilizes a predictive computational discovery platform to identify new drug targets and biomarkers. This innovative approach allows the company to streamline the drug development process, generating revenue through collaborations with pharmaceutical companies to develop and market new cancer treatments.
What is the highest forecasted price for CGEN Compugen Ltd.?
The highest price target for CGEN is $4.00 from Asthika Goonewardene at Truist Securities, which represents a 172.1% increase from the current price of $1.47.
What is the lowest forecasted price for CGEN Compugen Ltd.?
The lowest price target for CGEN is $4.00 from Asthika Goonewardene at Truist Securities, which represents a 172.1% increase from the current price of $1.47.
What is the overall CGEN consensus from analysts for Compugen Ltd.?
The overall analyst consensus for CGEN is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are CGEN stock price projections?
Stock price projections, including those for Compugen Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.